Publication:
Advances in the Treatment of Behcet's Disease

Simple item page
dc.contributor.authorALİBAZ ÖNER, FATMA
dc.contributor.authorsAlibaz-Oner, Fatma; Direskeneli, Haner
dc.date.accessioned2022-03-10T11:39:13Z
dc.date.available2022-03-10T11:39:13Z
dc.date.issued2021-06
dc.description.abstractPurpose of Review To assess current management of Behcet's disease (BD). Controversies on therapeutic approaches to different manifestations, whether conventional immunosuppressives (IS) or biologic agents, should be chosen, and options for refractory disease are discussed. Recent Findings Glucocorticoids are still the main agents for remission-induction and azathioprine the first-line conventional IS in maintenance phase to prevent relapses of major organ involvement. Apremilast is shown to be a safe and effective option approved by the FDA for oral ulcers. Large case series confirmed the efficacy and safety of TNF alpha inhibitors and Interferon-alpha. Promising results are observed with IL-1 inhibitors, ustekinumab, secukinumab, and tocilizumab for refractory BD. Although both conventional IS and biologic agents are effectively used to suppress inflammation in BD, there is still an unmet need for clear therapeutic strategies in the management for different manifestations. Further controlled studies with new biologic agents, anticoagulants and the benefit of concomitant IS usage with biologics are needed to optimize the management of BD.
dc.identifier.doi10.1007/s11926-021-01011-z
dc.identifier.eissn1534-6307
dc.identifier.issn1523-3774
dc.identifier.pubmed34014377
dc.identifier.urihttps://hdl.handle.net/11424/219843
dc.identifier.wosWOS:000652469700001
dc.language.isoeng
dc.publisherSPRINGER
dc.relation.ispartofCURRENT RHEUMATOLOGY REPORTS
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectBehcet&#8217
dc.subjects disease
dc.subjectTreatment
dc.subjectBiological agents
dc.subjectConventional immunosuppressives
dc.subjectLONG-TERM EFFICACY
dc.subjectREFRACTORY NEURO-BEHCET
dc.subjectANTI-TNF-ALPHA
dc.subjectFOLLOW-UP
dc.subjectINTERFERON ALPHA-2A
dc.subjectCYCLOSPORINE-A
dc.subjectDOUBLE-BLIND
dc.subjectOPEN-LABEL
dc.subjectMUCOCUTANEOUS MANIFESTATIONS
dc.subjectREMISSION INDUCTION
dc.titleAdvances in the Treatment of Behcet's Disease
dc.typereview
dspace.entity.typePublication
local.avesis.id111ebc75-1f11-42e9-b89b-c7bc96c586e5
local.import.packageSS4
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.articlenumber47
local.journal.numberofpages10
oaire.citation.issue6
oaire.citation.titleCURRENT RHEUMATOLOGY REPORTS
oaire.citation.volume23
relation.isAuthorOfPublicatione995a136-8c56-4192-bebe-fe522b567ef1
relation.isAuthorOfPublication.latestForDiscoverye995a136-8c56-4192-bebe-fe522b567ef1

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Alibaz-Oner and Direskeneli - 2021 - Advances in the Treatment of Behcet’s Disease.pdf
Size:
338.37 KB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs